Abstract
Background and objective
In developing countries, the dermatological manifestation of the human immunodeficiency virus (HIV) has a high prevalence. Apart from the systemic infection that ensues HIV, skin manifestations form a major part of the disease burden. They can present with atypical forms, and necessary tools for diagnosis may not be available in rural and remote parts of the country. Hence, they can stay misdiagnosed or undiagnosed, contributing to the morbidity of the patients. We attempted to enumerate the dermatologic opportunistic infections (OIs) in Rajkot city, Gujarat, India, in order to disseminate knowledge regarding the same.
Material and methods
It is a retrospective observational study. A total of 253 patients under treatment for HIV/acquired immunodeficiency syndrome (AIDS) at the ART Center (anti-retroviral therapy center) from 2011 to 2019 were included. The data recorded in the registry during the above-mentioned period were utilized in the study. The diagnoses of OIs were made clinically by multiple health care providers experienced in the field.
Result
Two hundred twenty-seven (227) of 253 (89.72%) of the patients had some form of dermatologic OI during the course of their treatment. Overall, fungal infections (33.03%) were most common, followed by bacterial infections (28.18%) and viral (14.55%) infections. Among the non-infectious causes, cheilitis/angular stomatitis topped the list. Among the STDs, herpes was the most common skin manifestation seen with a 10.57% prevalence. The CD4+ cell count for fungal infection ranged from 353-467 and was seen in stage 2 of the disease course. Bacterial infections were seen mainly during the early and middle stages of the disease while viral infections were most prevalent in stage 2 of the disease.
Conclusion
Skin manifestations can be useful clinical predictors of the disease stage, especially in resource-limited settings and in developing countries. They can present with unusual and atypical forms. Hence, knowledge about the prevalence of these OIs in a particular geographical area can be very useful for physicians in treating them and decreasing the disease burden.
Keywords: opportunistic infections, dermatologic manifestations, muco-cutaneous diseases, cd4+ cell count, hiv dermatoses
Introduction
The burden of skin diseases in human immunodeficiency virus (HIV) patients in developing countries is huge. It was reported that approximately 90% of people living with HIV have skin changes and symptoms during the course of their disease [1]. Skin findings are regarded by WHO as useful in assessing the severity of HIV infection in patients in a resource-limited environment [2].
Knowledge of the skin and mucosal signs of HIV/acquired immunodeficiency syndrome (AIDS) is important. Opportunistic infections (OIs) are usually the first manifestation of HIV, ensuring early diagnosis and prompt treatment, and reveals complications, as HIV causes atypical and severe presentations of these conditions [3]. Therefore, those involved in the health care of HIV patients must know the type, pattern, and prevalence of skin diseases in their locality [4-5].
These include Herpes zoster, varicella-zoster, bacillary angiomatosis, candidiasis, Kaposi sarcoma, common warts, and many others. They are related to low CD4+ cell counts and immunosuppression. But drug eruptions or inflammatory skin disease are due to health alteration of the immune system in the skin of HIV-positive patients [6].
HIV attacks the helper/inducer T cells (CD4+ cells), resulting in syncytial formation and lysis with slow but progressive destruction of this cell population. Therefore, it is a reliable prognostic indicator of immune response to therapy [7-8]. In general, the CD4+ cells (%CD4+ or absolute count) progressively decreases as HIV disease advances [9]. As very few studies have been done in our locality, we have attempted to do the same to increase awareness among physicians regarding the prevalence of these dermatologic OIs.
Materials and methods
The study design is a retrospective observational study. The data of patients from January 2011 to April 2019 enrolled at the ART Centre, Rajkot, Gujarat, India, were collected. The study population consists of 253 HIV seropositive patients with AIDS-defining illnesses, out of which 227 patients had mucocutaneous OIs. The diagnosis of the dermatological manifestation was made clinically. We included all seropositive patients with OIs from all age groups. The only exclusion criteria in our study were patients with missing or incomplete data. The data were collected, sorted, and analyzed by the authors in this study. It is a descriptive study, and no statistical analysis was performed. IRB approval from the ethics committee and informed consent were obtained from all the patients in the study.
Results
Overall fungal infections (dermatophytosis, candida) accounted for most of the opportunistic infections (33.03%). This is because cell-mediated immunity is the major mechanism of controlling normal fungal commensals from flourishing. In HIV patients, cell-mediated immunity is down, which allows these fungal commensals to grow and cause infection. Among others, furuncle (20.26%) and angular stomatitis/cheilitis (13.21%) accounted for most dermatologic manifestations. The impaired skin barrier and severe neutropenia may be the causes of such a finding. A summary of the prevalence of all the dermatologic OIs can be found in Table 1 and the graphical presentation in Figure 1.
Table 1. Prevalence of dermatological opportunistic infections in the study population.
*n is the total number of patients with dermatological manifestations.
| Infectious Disorder | Total(n=227)* |
| Fungal | 75(33.03%) |
| Furuncle | 46(20.26%) |
| Angular Stomatitis/Cheilitis | 30(13.21%) |
| Herpes | 24(10.57%) |
| Seborrheic Dermatitis | 13(5.72%) |
| Folliculitis | 8(3.52%) |
| Scabies | 6(2.64%) |
| Abscess | 5(2.2%) |
| Chicken Pox | 4(1.76%) |
| Syphilis | 4(1.76%) |
| Genital Warts | 3(1.32%) |
| Lichen Planus | 3(1.32%) |
| Eczema | 2(0.9%) |
| Molluscum Contagiosum | 2(0.9%) |
| Atopic Dermatitis | 1(0.44%) |
| Non Herpetic Chancroid | 1(0.44%) |
Figure 1. Graphical presentation of the prevalence of dermatological opportunistic infections.
The number of dermatologic manifestations progressively increased as the CD4+ cell count went down. Chickenpox and furuncle were found in stage 1 of the disease with a mean CD4+ cell count of >500 cells/mm3. In stages 2 and 3 of the disease, the majority of the dermatoses were found, including infectious and non-infectious causes. A summary of the same findings can be seen in Table 2 and Table 3.
Table 2. Co-relation of dermatological opportunistic infections with CD4+ cell count.
| Infectious Disorders | CD4+ Cell Count Range (cells/mm3) | Mean CD4+ Cell Count (cells/mm3) |
| Chicken Pox | 558-874 | 600 |
| Scabies | 233-275 | 250 |
| Furuncle | 510-660 | 550 |
| Folliculitis | 200-250 | 220 |
| Seborrheic Dermatitis | 360-480 | 400 |
| Fungal | 353-467 | 400 |
| Molluscum Contagiosum | 100-200 | 150 |
| Atopic Dermatitis | 290 | 290 |
| Herpes | 371-410 | 390 |
| Angular Stomatitis/Cheilitis | 288-320 | 300 |
| Genital Warts | 270-300 | 280 |
| Eczema | 367-455 | 400 |
| Abscess | 100-550 | 250 |
| Lichen Planus | 250-323 | 270 |
| Syphilis | 200-330 | 300 |
| Non-Herpetic Chancroid | 450 | 450 |
Table 3. Immunologic staging of dermatological opportunistic infections.
| Dermatological Manifestations | CD4+ Cell Count (cells/mm3) | Immunologic Staging(WHO) |
| Chickenpox | More than or equal to 500 | Stage 1 |
| Furuncle | ||
| Seborrheic Dermatitis | 350 to 499 | Stage 2 |
| Fungal Infection | ||
| Herpes | ||
| Eczema | ||
| Non-Herpetic Chancroid | ||
| Angular Stomatitis/Cheilitis | 200 to 349 | Stage 3 |
| Atopic Dermatitis | ||
| Genital Warts | ||
| Scabies | ||
| Folliculitis | ||
| Lichen Planus | ||
| Syphilis | ||
| Molluscum Contagiosum | Less than 200 | Stage 4 |
Among all the sexually transmitted diseases (STDs), herpes accounts for most of the dermatoses followed by a few cases of syphilis, genital warts, and molluscum contagiosum. We also found a single case of chancroid in our study. A summary of these findings is represented in Table 4 and graphically presented in Figure 2.
Table 4. Prevalence of sexually transmitted diseases as part of opportunistic infections.
| Sexually Transmitted Diseases | Total (n=227) |
| Herpes Infection | 24 (10.57%) |
| Syphilis | 4 (1.76%) |
| Genital Warts | 3 (1.32%) |
| Molluscum Contagiosum | 2 (0.88%) |
| Chancroid | 1 (0.44%) |
| Gonorhhoea | 0 (0%) |
| Donovanosis | 0 (0%) |
Figure 2. Graphical presentation of the prevalence of sexually transmitted diseases.
Discussion
The introduction of highly active antiretroviral therapy (HAART) has drastically changed the natural course of HIV and decreased the incidence of OIs by decreasing the viral load and increasing the CD4+ cell count [10-11]. The immune restoration syndrome that arises due to recovery of the immune system by HAART has been implicated in the development of previously dormant infections, e.g. herpes zoster, mycobacterial infections, etc. [12-13]. These drugs are also responsible for inflammatory adverse drug reactions [14]. In this study, we focused on mucocutaneous OIs regardless of their HAART status. The tertiary care center where this study was conducted was the referral site for all the surrounding rural areas and, therefore, the study population was a good representation of the actual population.
Out of 253 seropositive patients, 227 (89.72%) patients had some form of dermatologic OIs at some point during their treatment. It was similar to studies done by Singh et al. (87.6%) [15], Jeffrey et al. (86%) [16], and Pitche et al. (82.5%) [17], whereas a study done by Spira et al. [18] showed that it is relatively lower (65.3%).
We found that the most common dermatoses in HIV were due to infection (77.36%), which is slightly higher than studies done by Oninla (65.2%) [19] and Salami et al. (64.2%) [20], who also found infection as the most common cause. Infections start to develop in the early stages of HIV while progressing to more diffuse forms in the later stages of the disease [21-22], which was seen in our study.
Overall fungal infection (candida, dermatophytosis) (33.03%) was the most common mucocutaneous manifestation. Similar findings were also seen in studies done by Singh et al. [15] and Spira et al. [18]. Among other infectious manifestations, bacterial infections (28.18%) and viral infections (14.55%) were the most common. These findings were comparable to studies done by Oninla (50%, 12%, and 3.2%) [19] for the prevalence of fungal, viral, and bacterial dermatologic manifestations, respectively, and the Salami (37% and 24.3%) [20] prevalence for fungal and viral manifestations.
Seborrheic dermatitis (5.72%) is frequently found to be the most common dermatologic manifestation but that was not seen in our study [4,15]. In the present study, angular cheilitis/stomatitis was found to be the most common non-infectious dermatologic manifestation at 13.21%.
Among all the sexually transmitted diseases, herpes infection accounted for most of them (6%), which was comparable to other studies [19]. Other STDs found in the present study were syphilis (1.76%), genital warts (1.32%), molluscum contagiosum (0.88%), and chancroid (0.44%).
The co-relation to CD4+ cell count that we observed in our study co-related well with the World Health Organization (WHO) staging of the disease. As the disease progressed, the number of dermatoses observed increased. Similar results were seen in studies done by Wiwanitkit [23] and Nnoruka et al. [22]. Sivayathorn et al. mentioned that the number of dermatoses found in stages 2 and 3 was more as compared to stage 1 [24].
Fungal infections were predominantly seen in stage 2 of the disease in the present study, but they were not exclusive to these stages. Sharma et al. [25] and Goh et al. [26] reported <200 cells/mm3 CD4+ cell count for oral candidiasis. Oral candidiasis particularly extending to the esophagus is associated with severe immunosuppression and therefore these are good clinical indicators of advanced HIV infection [19].
Bacterial infections were found to be prevalent in the early and middle part of the clinical staging of HIV with CD4+ cell count ranging from 200-660 cells/mm3. Nnoruka et al. found bacterial infections in the CD4+ cell count range of 200 to 500 cells/mm3.
Viral infections were found in all the stages of the disease with herpes being most prevalent in the second stage. WHO has also classified it as a second-stage disease. In the present study, genital warts were found in those with stage 3 of HIV. WHO, however, has classified it in stage 2. Mawenzi et al. have mentioned in their study that genital warts are more prevalent in patients with a CD4+ cell count of >300 cells/mm3 [27].
Seborrheic dermatosis was found to be in stage 2 in the present study, which is similar to where WHO has listed the disease. This finding is similar to the ones found by Oninla [19] and Nnoruka [22].
Conclusions
Mucocutaneous manifestations of HIV are not only the cause of morbidity and serious concern to the patients but are of great help in the early identification of cases of HIV patients. Many such manifestations are a marker of AIDS. Both infectious and noninfectious causes are responsible for morbidity in these patients. These manifestations can be taken care of with appropriate precautions and medications. There is a definite correlation between CD4+ cell count and mucocutaneous manifestations of HIV. In the search for reliable clinical indicators for the management of HIV/AIDS in resource-poor settings, mucocutaneous disorders of HIV should be considered among key clinical indicators for the prediction of underlying immune status, disease progression, and possible complications of highly active antiretroviral therapy.
Acknowledgments
Sanket D. Basida, Brinda Basida, Nirav Zalavadiya, and Arti P. Trivedi are all co-first authors.
The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.
The authors have declared that no competing interests exist.
Human Ethics
Consent was obtained or waived by all participants in this study. Institutional Review Board, P.D.U. Medical College, Rajkot issued approval NA
Animal Ethics
Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.
References
- 1.Cutaneous manifestation of HIV/AIDS: part 1. Dlova N, Mosam A. https://www.ajol.info/index.php/sajhivm/article/view/34816 South Afr J HIV Med. 2004;5:12–17. [Google Scholar]
- 2.World Health Organization. Geneva, Switzerland: WHO; 2007. Who Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-Related Disease in Adults and Children. [Google Scholar]
- 3.Common skin and mucosal disorders in HIV/AIDS. Jordaan HF. S Afr Fam Pract. 2008;50:14–23. [Google Scholar]
- 4.Dermatological findings correlated with CD4 lymphocyte counts in a prospective 3 year study of 1161 patients with human immunodeficiency virus disease predominantly acquired through intravenous drug abuse. Muñoz-Pérez MA, Rodriguez-Pichardo A, Camacho F, Colmenero MA. Br J Dermatol. 1998;139:33–39. doi: 10.1046/j.1365-2133.1998.02310.x. [DOI] [PubMed] [Google Scholar]
- 5.Natural history and spectrum of disease in adults with HIV/AIDs in Africa. Grant AD, Djomand G, De Cock KM. https://pubmed.ncbi.nlm.nih.gov/9416366/ AIDS (London, England) 1997;11:0–54. [PubMed] [Google Scholar]
- 6.New insights into HIV-1-primary skin disorders. Cedeno-Laurent F, Gómez-Flores M, Mendez N, Ancer-Rodríguez J, Bryant JL, Gaspari AA, Trujillo JR. J Int AIDS Soc. 2011;14:5. doi: 10.1186/1758-2652-14-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Correlation between cutaneous manifestation and degree of immunosuppression (CD-4 count) in seropositive patients- a study done in tertiary level hospital of western Rajasthan, India. Prakash P, Mal C, Mathur A, Singhi M. https://www.ijcmas.com/vol-4-7/Prabhu%20Prakash,%20et%20al.pdf Int J Curr Microbiol. 2015;4:498–510. [Google Scholar]
- 8.Baseline CD4 lymphocyte count among HIV patients in Kano, Northern Nigeria. Nwokedi E. Ochicha O, Aminu Z, Nasiru M. Afr J Health Sci. 2007;14:3–4. [Google Scholar]
- 9.HIV patients with dermatological manifestations correlated with CD4. Premanandham N, Kante M, Reddy P. https://www.ijcmas.com/vol-4-2/N.Premanadham2,%20et%20al.pdf Int J Curr Microbio App Sci. 2015;4:575–581. [Google Scholar]
- 10.HIV-protease inhibitors. Flexner C. N Engl J Med. 1998;338:1281–1293. doi: 10.1056/NEJM199804303381808. [DOI] [PubMed] [Google Scholar]
- 11.Update on the cutaneous manifestations of HIV infection. Clinical and pathologic features. Aftergut K, Cockerell CJ. Dermatol Clin. 1999;17:445–471. doi: 10.1016/s0733-8635(05)70101-7. [DOI] [PubMed] [Google Scholar]
- 12.Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. Domingo P, Torres OH, Ris J, Vazquez G. Am J Med. 2001;110:605–609. doi: 10.1016/s0002-9343(01)00703-3. [DOI] [PubMed] [Google Scholar]
- 13.Highly active antiretroviral therapy. French M, Lenzo N, John M, Mallal S, Price P. Lancet. 1998;351:1056–1057. doi: 10.1016/S0140-6736(05)79021-8. [DOI] [PubMed] [Google Scholar]
- 14.Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor. Calista D, Morri M, Stagno A, Boschini A. Am J Clin Dermatol. 2002;3:59–62. doi: 10.2165/00128071-200203010-00006. [DOI] [PubMed] [Google Scholar]
- 15.Dermatological manifestations in HIV-infected patients at a tertiary care hospital in a tribal (Bastar) region of Chhattisgarh, India. Singh H, Singh P, Tiwari P, Dey V, Dulhani N, Singh A. Indian J Dermatol. 2009;54:338–341. doi: 10.4103/0019-5154.57609. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Dermatologic manifestations in HIV-infected patients: a primary care perspective. Samet JH, Muz P, Cabral P, Jhamb K, Suwanchinda A, Freedberg KA. https://doi.org/10.4065/74.7.658. Mayo Clin Proc. 1999;74:658–660. doi: 10.4065/74.7.658. [DOI] [PubMed] [Google Scholar]
- 17.Prevalence of skin disease in AIDS patients in the Lome-Tokoin Teaching Hospital of Togo. Pitche P, Tchangai-Walla K, Napo-Koura G, Mijiyawa M, Agbere A, Tatagan A. Cahiers d'études et de recherches francophones/Santé. 1995;5:349–352. [PubMed] [Google Scholar]
- 18.Prevalence of cutaneous disorders in a population of HIV-infected patients. Southwestern France, 1996. Spira R, Mignard M, Doutre MS, Morlat P, Dabis F. Arch Dermatol. 1998;134:1208–1212. doi: 10.1001/archderm.134.10.1208. [DOI] [PubMed] [Google Scholar]
- 19.Mucocutaneous manifestations of HIV and the correlation with WHO clinical staging in a tertiary hospital in Nigeria. Oninla OA. AIDS Res Treat. 2014;2014:360970. doi: 10.1155/2014/360970. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Pattern of cutaneous pathology among a cohort of HIV/AIDS patients accessing care in a rural/suburban adult ART clinic in Nigeria. Salami TA, Adewuyi GM, Echekwube P, Affusim C. https://www.journaljammr.com/index.php/JAMMR/article/view/13073 J Adv Med Med Res. 2013;3:1199–1207. [Google Scholar]
- 21.Skin disease: clinical indicator of immune status in human immunodeficiency virus (HIV) infection. Raju PV, Rao GR, Ramani TV, Vandana S. Int J Dermatol. 2005;44:646–649. doi: 10.1111/j.1365-4632.2004.02067.x. [DOI] [PubMed] [Google Scholar]
- 22.Correlation of mucocutaneous manifestations of HIV/AIDS infection with CD4 counts and disease progression. Nnoruka EN, Chukwuka JC, Anisuiba B. Int J Dermatol. 2007;46 Suppl 2:14–18. doi: 10.1111/j.1365-4632.2007.03349.x. [DOI] [PubMed] [Google Scholar]
- 23.Prevalence of dermatological disorders in Thai HIV-infected patients correlated with different CD4 lymphocyte count statuses: a note on 120 cases. Wiwanitkit V. Int J Dermatol. 2004;43:265–268. doi: 10.1111/j.1365-4632.2004.01649.x. [DOI] [PubMed] [Google Scholar]
- 24.Prevalence of skin disease in patients infected with human immunodeficiency virus in Bangkok, Thailand. Sivayathorn A, Srihra B, Leesanguankul W. https://pubmed.ncbi.nlm.nih.gov/8849182/ Ann Acad Med Singap. 1995;24:528–533. [PubMed] [Google Scholar]
- 25.Orocutaneous manifestations as markers of disease progression in HIV infection in Indian setting. Sharma YK, Sawhney M, Bhakuni DS, Gera V. Med J Armed Forces India. 2004;60:239–243. doi: 10.1016/S0377-1237(04)80054-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Spectrum of skin disorders in human immunodeficiency virus-infected patients in Singapore and the relationship to CD4 lymphocyte counts. Goh BK, Chan RK, Sen P, Theng CT, Tan HH, Wu YJ, Paton NI. Int J Dermatol. 2007;46:695–699. doi: 10.1111/j.1365-4632.2007.03164.x. [DOI] [PubMed] [Google Scholar]
- 27.Epidemiology and clinical spectrum of cutaneous diseases manifesting among newly diagnosed HIV seropositive adults in Nakuru county-Kenya. Mawenzi RL, Oguttu OR, Williams HC, Joash A. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.367.7885&rep=rep1&type=pdf Continental J Med Res. 2013;7:1–9. [Google Scholar]


